Hualan Biological Engineering Inc(002007) vaccine Co., Ltd
Initial public offering and listing on GEM
Suggestive announcement of listing announcement
Sponsor (lead underwriter): Huatai United Securities Co., Ltd
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Upon examination and approval of Shenzhen Stock Exchange, Hualan Biological Engineering Inc(002007) vaccine Co., Ltd. (hereinafter referred to as “the company”) will list its RMB common shares on the gem of Shenzhen Stock Exchange on February 18, 2022. The full text of the listing announcement and the full text of the prospectus for the initial public offering of shares are disclosed on the websites designated by the CSRC (cninfo, www.cn. Info. Com. CN; CSI, www.cs. Com. CN; China Securities, www.cn. Stock. Com; securities times, www.stcn. Com; Securities Daily, www.zqrb. CN), For investors to consult.
QR code of web page: cninfo.com I. listing overview
(I) stock abbreviation: Hualan vaccine
(II) Stock Code: 301207
(III) total share capital after IPO: 40001 million shares
(IV) increased shares in the initial public offering: 40.01 million shares. All the shares issued this time are new shares without the transfer of old shares. 2、 Risk tips
The company’s shares will be listed on the growth enterprise market of Shenzhen Stock Exchange, which has high investment risk. GEM companies have the characteristics of unstable performance, high operation risk and high delisting risk, and investors are facing greater market risk. Investors shall fully understand the investment risks of the gem and the risk factors disclosed by the company, and make investment decisions prudently.
The offering price is 56.88 yuan / share, which does not exceed the median and weighted average of offline investors’ quotations after excluding the highest quotation, as well as the securities investment fund, national social security fund, basic old-age insurance fund, etc. established through public offering after excluding the highest quotation The enterprise annuity fund established in accordance with the measures for the administration of enterprise annuity fund and the insurance fund quotation median and weighted average in accordance with the measures for the administration of the use of insurance funds, whichever is lower. According to the industry classification guidelines for Listed Companies formulated by the CSRC, the industry of the issuer is “C27 pharmaceutical manufacturing industry”, and the static average p / E ratio of “C27 pharmaceutical manufacturing industry” published by China Securities Index Co., Ltd. in the latest month is 39.05 times (as of January 26, T-4, 2022). The valuation levels of comparable listed companies are as follows:
T-4 closing price 2020 deduction 2020 deduction 2020 deduction 2020 deduction securities code securities abbreviation (January 26, 2022, non front EPS, non rear EPS, non front P / E, non rear P / e day, RMB) (yuan / share) (yuan / share)
300601.SZ Shenzhen Kangtai Biological Products Co.Ltd(300601) 81.55 0.9886 0.9031 82.49 90.30
300122.SZ Chongqing Zhifei Biological Products Co.Ltd(300122) 107.94 2.0633 2.0768 52.31 51.97
300142.SZ Walvax Biotechnology Co.Ltd(300142) 48.84 0.6305 0.4494 77.47 108.68
300841.SZ Chengdu Kanghua Biological Products Co.Ltd(300841) 218.99 4.5338 4.4773 48.30 48.91
688739.SH Liaoning Chengda Biotechnology Co.Ltd(688739) 69.77 2.2048 2.0280 31.64 34.40
688276.SH Changchun Bcht Biotechnology Co(688276) 55.90 1.0131 0.9735 55.18 57.42
688670.SH Jiangsu Gdk Biological Technology Co.Ltd(688670) 64.45 1.7611 1.8396 36.60 35.03
Average 54.86 60.96
Source: wind data, as of January 26, 2022 (T-4)
Note 1: if there is mantissa difference in the calculation of P / E ratio, it is caused by rounding;
Note 2: EPS before / after deduction of non recurring profit and loss in 2020 = net profit attributable to the parent before / after deduction of non recurring profit and loss in 2020 / total share capital on T-4 day; The issuance price of 56.88 yuan / share corresponds to the lower diluted P / E ratio of the issuer’s net profit attributable to the parent before and after deducting non recurring profits and losses in 2020, which is 25.31 times, lower than the average static P / E ratio of “C27 pharmaceutical manufacturing industry” published by China Securities Index Co., Ltd. on January 26, 2022 (T-4), and lower than the average static P / E ratio of comparable companies after deducting non recurring profits and losses in 2020, However, there is still a risk that the decline of the issuer’s share price will bring losses to investors in the future.
The issuer and the recommendation institution (lead underwriter) remind investors to pay full attention to the risk factors contained in the pricing marketization, know that the stock may fall below the issue price after listing, effectively improve the risk awareness, strengthen the value investment concept, avoid blind speculation, carefully study and judge the rationality of the issue pricing, and make rational investment decisions.
There is a risk that the net asset scale will increase significantly due to the acquisition of raised funds, which will have an important impact on the issuer’s production and operation mode, operation management and risk control ability, financial status, profitability and long-term interests of shareholders.
The issuer and the recommendation institution (lead underwriter) remind investors to pay attention to investment risks, carefully study and judge the rationality of issuance pricing, and make investment decisions rationally. 3、 Contact information
1. Contact address and telephone number of the issuer
Issuer: Hualan Biological Engineering Inc(002007) vaccine Co., Ltd
Contact address: No. 1-1, No. a, Hualan Avenue, Xinxiang City, Henan Province
Contact: LV Chengyu
Tel.: 0373-3559909
2. Contact address and telephone number of recommendation institution and recommendation representative
Sponsor (lead underwriter): Huatai United Securities Co., Ltd
Sponsor representatives: Jia Peng, Liu Xiaoning
Contact address: 6 / F, block a, Fengming international building, No. 22 Fengsheng Hutong, Xicheng District, Beijing
Tel: 010-56839300
(there is no text on this page, which is the signature page of the suggestive announcement of Hualan Biological Engineering Inc(002007) vaccine Co., Ltd. initial public offering and listing on the GEM)
Hualan Biological Engineering Inc(002007) vaccine Co., Ltd. (there is no text on this page, which is the signature page of Huatai United Securities Co., Ltd. on the suggestive announcement of Hualan Biological Engineering Inc(002007) vaccine Co., Ltd. initial public offering and listing on GEM)
Huatai United Securities Co., Ltd
